Open Access

MicroRNA‑1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib

  • Authors:
    • Qianqian Yu
    • Yiqian Liu
    • Chengcai Wen
    • Yongzhao Zhao
    • Shidai Jin
    • Youfang Hu
    • Feng Wang
    • Liang Chen
    • Bin Zhang
    • Wei Wang
    • Quan Zhu
    • Renhua Guo
  • View Affiliations

  • Published online on: November 9, 2017     https://doi.org/10.3892/ol.2017.7378
  • Pages:963-971
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

Dysregulation of microRNAs in various types of human cancer promote or suppress oncogenesis. MicroRNA (miR)‑1 was previously revealed to function as a tumor suppressor in prostate cancer cells, and its expression was associated with reduced metastatic potential in lung cancer. The present study investigated the role of miR‑1 and its association with phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic subunit α (PIK3CA) in the pathophysiology of esophageal squamous cell carcinoma (ESCC), and analyzed the effects of miR‑1 inhibitor or mimics on sensitivity to epidermal growth factor receptor‑tyrosine kinase inhibitors, the alterations of cell cycle distribution and apoptosis in ESCC cells. Compared with normal tissues, the level of miR‑1 expression was significantly lower and PIK3CA expression was higher in ESCC tissues. The level of miR‑1 expression was also inversely associated with the level of PIK3CA mRNA expression. Low miR‑1 and high PIK3CA expression levels were strongly associated with lymph node metastasis, and the level of miR‑1 expression was negatively associated with clinical Tumor‑Node‑Metastasis stage. Furthermore, exogenous expression of miR‑1 inhibited growth, arrested cell cycle in the G1 phase and increased apoptosis in ESCC cells, whereas it decreased PIK3CA protein expression levels. Furthermore, overexpression of miR‑1 increased the sensitivity of ESCC cells to the anticancer drug, gefitinib. A possible mechanism for this increased sensitivity to gefitinib may be inactivation of the PIK3CA signaling pathway. To the best of our knowledge, this is the first time that the results of the present study demonstrated that miR‑1 upregulation may be a potential strategy for the treatment of human ESCC.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yu, Q., Liu, Y., Wen, C., Zhao, Y., Jin, S., Hu, Y. ... Guo, R. (2018). MicroRNA‑1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib. Oncology Letters, 15, 963-971. https://doi.org/10.3892/ol.2017.7378
MLA
Yu, Q., Liu, Y., Wen, C., Zhao, Y., Jin, S., Hu, Y., Wang, F., Chen, L., Zhang, B., Wang, W., Zhu, Q., Guo, R."MicroRNA‑1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib". Oncology Letters 15.1 (2018): 963-971.
Chicago
Yu, Q., Liu, Y., Wen, C., Zhao, Y., Jin, S., Hu, Y., Wang, F., Chen, L., Zhang, B., Wang, W., Zhu, Q., Guo, R."MicroRNA‑1 inhibits tumorigenicity of esophageal squamous cell carcinoma and enhances sensitivity to gefitinib". Oncology Letters 15, no. 1 (2018): 963-971. https://doi.org/10.3892/ol.2017.7378